Meningococcal vaccine groups A C W135 and Y polysaccharide - Pfizer

Drug Profile

Meningococcal vaccine groups A C W135 and Y polysaccharide - Pfizer

Alternative Names: ACWY Vax; Mencevax ACWY

Latest Information Update: 06 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 01 Oct 2015 Pfizer acquires meningococcal vaccine groups A, C, W135 and Y polysaccharide from GlaxoSmithKline
  • 22 Jun 2015 Pfizer enters into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, including Mencevax vaccine ,
  • 22 Jun 2015 Registered for Meningococcal infections (In adolescents, In adults, In children, Prevention) in Middle East, Latin America, Europe, Australia, Africa, Asia (SC) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top